keyword
https://read.qxmd.com/read/38389602/analysis-of-drugs-prescribed-to-elderly-patients-in-a-tertiary-health-care-center-in-raipur-central-india-an-observational-study
#21
JOURNAL ARTICLE
Yogendra Keche, Nitin R Gaikwad, Preetam N Wasnik, Keshao Nagpure, Md Sabah Siddiqui, Apoorva Joshi, Suryaprakash Dhaneria, Gevesh Dewangan, Jhasaketan Meher, Pranita Das
Background Most elderly patients suffer from multiple diseases and are on multiple drugs for treatment. Polypharmacy in the elderly, physiological changes with old age, changes in the pharmacokinetics and pharmacodynamic effects of many drugs, and newer drug prescription trends for diseases like diabetes and cardiovascular disease make drug prescribing in the elderly more difficult. There are many chances of drug-drug interactions with easily available over-the-counter (OTC) medications. To prevent the irrational use of drugs in the elderly, there is a need for prescription analysis studies...
January 2024: Curēus
https://read.qxmd.com/read/38380420/efficacy-and-safety-of-triple-therapy-of-telmisartan-amlodipine-rosuvastatin-in-patients-with-dyslipidemia-and-hypertension-a-multicenter-randomized-clinical-trial
#22
JOURNAL ARTICLE
Sungjoon Park, Doyeon Hwang, Jeehoon Kang, Jung-Kyu Han, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Jin-Man Cho, Byung-Ryul Cho, Sung Gyun Ahn, Seok-Min Kang, Jung-Hoon Sung, Ung Kim, Namho Lee, Hyo-Soo Kim
BACKGROUND: Hypertension and dyslipidemia significantly contribute to cardiovascular disease development. Their coexistence poses challenges in managing multiple medications, influencing treatment adherence. OBJECTIVE: This study aimed to assess the efficacy and safety of a combined treatment approach using a fixed-dose combination therapy. METHODS: This multicenter, 8-week, randomized, double-blind, Phase IV trial was named Telmisartan/Amlodipine/Rosuvastatin from Samjin Pharmaceuticals and evaluated the efficacy and safety of fixed-dose combination treatment in patients with essential hypertension and dyslipidemia...
2024: Current Therapeutic Research, Clinical and Experimental
https://read.qxmd.com/read/38380162/a-comprehensive-quality-control-and-cost-comparison-study-of-branded-and-generic-angiotensin-receptor-blockers
#23
JOURNAL ARTICLE
Arvind Kumar Sharma, Shruti Rastogi, Faraat Ali, Anuj Prakash Yadav, Ramesh K Goyal
This study was designed to assess both the quality and cost aspects of various branded and generic formulations of angiotensin receptor blockers, specifically Irbesartan, Losartan Potassium, Olmesartan Medoxomil, Telmisartan, and Valsartan. The collected samples underwent distinct quality evaluations using the methods outlined in different global Pharmacopoeias (British Pharmacopoeia/European Pharmacopoeia, Indian Pharmacopoeia and United States Pharmacopoeia). These drugs were characterized using Fourier-Transform Infrared Spectroscopy and Nuclear Magnetic Resonance techniques, while their quality and concentration were analysed using High Performance Liquid Chromatography...
March 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/38380147/nanofabrications-of-erythrocyte-membrane-coated-telmisartan-delivery-system-effective-for-radiosensitivity-of-tumor-cells-in-mice-model
#24
JOURNAL ARTICLE
Shaoqing Chen, Cheng Wang, Yanyan Meng, Pengyin Li, Yiwen Pan, Mu He, Xinye Ni
BACKGROUND: Radiation stimulates the secretion of tumor stroma and induces resistance, recurrence, and metastasis of stromal-vascular tumors during radiotherapy. The proliferation and activation of tumor-associated fibroblasts (TAFs) are important reasons for the production of tumor stroma. Telmisartan (Tel) can inhibit the proliferation and activation of TAFs (resting TAFs), which may promote radiosensitization. However, Tel has a poor water solubility. METHODS: In this study, self-assembled telmisartan nanoparticles (Tel NPs) were prepared by aqueous solvent diffusion method to solve the insoluble problem of Tel and achieve high drug loading of Tel...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38377553/intestinal-absorption-of-nanoparticles-to-reduce-oxidative-stress-and-vasoconstriction-for-treating-diabetic-nephropathy
#25
JOURNAL ARTICLE
Chenxin Liu, Mengxue Pang, Qingyu Wang, Mei Yan, Yingying Zhou, Hanchun Yao, Bin Du
The etiology of diabetic nephropathy (DN) is complex, and the incidence is increasing year by year. The patient's kidney showed oxidative stress damage, increasing active oxygen species (ROS) content, and vasoconstriction. Due to poor drug solubility and low renal accumulation, the current treatment regimens have not effectively alleviated glomerulopathy and other kidney damage caused by DN. Therefore, it is of great significance to explore new treatment strategies and drug delivery systems. Here, we constructed an oral nanodelivery system (Tel/CAN@CS-DA) that reduced oxidative stress and vasoconstriction...
February 20, 2024: ACS Biomaterials Science & Engineering
https://read.qxmd.com/read/38371656/rationale-for-a-new-low-dose-triple-single-pill-combination-for-the-treatment-of-hypertension
#26
JOURNAL ARTICLE
Anthony Rodgers, Abdul Salam, William Cushman, Asita de Silva, Gian Luca Di Tanna, Sonali R Gnanenthiran, Diederick Grobbee, Krzysztof Narkiewicz, Dike Ojji, Suzanne Oparil, Neil Poulter, Markus P Schlaich, Aletta E Schutte, Wilko Spiering, Bryan Williams, Jackson T Wright, Paul Whelton
Two recent large trials showed the potential of single pill combinations (SPCs) with ≥3 low-dose components among people with hypertension who were untreated or receiving monotherapy. In both trials, these 'hypertension polypills' were superior to usual care, achieving >80% BP control without increasing withdrawal due to side effects. However, there are no such products available for prescribers. To address this unmet need, George Medicines developed GMRx2 with telmisartan/amlodipine/indapamide in three strengths (mg): 10/1...
2024: Global Heart
https://read.qxmd.com/read/38368444/angiotensin-type-1-receptor-activation-promotes-neuronal-and-glial-alpha-synuclein-aggregation-and-transmission
#27
JOURNAL ARTICLE
Lucia Lage, Ana I Rodriguez-Perez, Begoña Villar-Cheda, Jose L Labandeira-Garcia, Antonio Dominguez-Meijide
The brain renin-angiotensin system (RAS) has been related to dopaminergic degeneration, and high expression of the angiotensin II (AngII) type 1 receptor (AT1) gene is a marker of the most vulnerable neurons in humans. However, it is unknown whether AngII/AT1 overactivation affects α-synuclein aggregation and transmission. In vitro, AngII/AT1 activation increased α-synuclein aggregation in dopaminergic neurons and microglial cells, which was related to AngII-induced NADPH-oxidase activation and intracellular calcium raising...
February 17, 2024: NPJ Parkinson's Disease
https://read.qxmd.com/read/38367290/telmisartan-loading-thermosensitive-hydrogel-repairs-gut-epithelial-barrier-for-alleviating-inflammatory-bowel-disease
#28
JOURNAL ARTICLE
Lu Xu, Qin Zhao, Yiqiong Xie, Ge Bai, Hongwen Liu, Qi Chen, Hongjue Duan, Lishan Wang, Hang Xu, Yuxiang Sun, Gao Ling, Weihong Ge, Yun Zhu
Inflammatory bowel disease (IBD) remains a global health concern with a complex and incompletely understood pathogenesis. In the course of IBD development, damage to intestinal epithelial cells and a reduction in the expression of tight junction (TJ) proteins compromise the integrity of the intestinal barrier, exacerbating inflammation. Notably, the renin-angiotensin system and angiotensin II receptor type 1 (AT1R) play a crucial role in regulating the pathological progression including vascular permeability, and immune microenvironment...
February 14, 2024: Colloids and Surfaces. B, Biointerfaces
https://read.qxmd.com/read/38319595/efficacy-and-safety-of-combination-therapy-with-telmisartan-rosuvastatin-and-ezetimibe-in-patients-with-dyslipidemia-and-hypertension-a-randomized-double-blind-multicenter-therapeutic-confirmatory-phase-iii-clinical-trial
#29
JOURNAL ARTICLE
Chan Joo Lee, Woong Chol Kang, Sang Hyun Ihm, Il Suk Sohn, Jong Shin Woo, Jin Won Kim, Soon Jun Hong, Jung Hyun Choi, Jung-Won Suh, Jae-Bin Seo, Joon-Hyung Doh, Jung-Woo Son, Jae-Hyeong Park, Ju-Hee Lee, Young Joon Hong, Jung Ho Heo, Jinho Shin, Seok-Min Kang
This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control and cholesterol-lowering effects and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe versus rosuvastatin and ezetimibe double therapy or telmisartan single therapy in dyslipidemia patients with hypertension. After a wash-out/therapeutic lifestyle change period of ≥4 weeks, a total of 100 eligible patients were randomized and received one of three treatments for 8 weeks: (1) telmisartan 80 mg/rosuvastatin 20 mg/ezetimibe 10 mg (TRE), (2) rosuvastatin 20 mg/ezetimibe 10 mg (RE), or (3) telmisartan 80 mg (T)...
February 6, 2024: Journal of Clinical Hypertension
https://read.qxmd.com/read/38311886/comparison-of-effects-of-telmisartan-versus-valsartan-on-post-induction-hypotension-during-noncardiac-surgery-a-prospective-observational-study
#30
JOURNAL ARTICLE
Chung-Sik Oh, Jun Young Park, Seong-Hyop Kim
BACKGROUND: Telmisartan is considered more potent than valsartan. Hemodynamic response during anesthesia induction may be influenced by anti-hypertension (HTN) medication. The present study compared the effect of anti-HTN medications on post-induction hypotension during noncardiac surgeries. METHODS: This observational study standardized the anesthetic regimen across patients, with hypotension defined as mean blood pressure (BP) of less than 65 mmHg. The hemodynamic changes within 5 min before and after endotracheal intubation, and within 10 min before and after surgical incision were measured...
February 5, 2024: Korean Journal of Anesthesiology
https://read.qxmd.com/read/38305876/renal-and-cardiac-effects-of-the-pde9-inhibitor-bay-73-6691-in-5-6-nephrectomized-rats
#31
JOURNAL ARTICLE
Xin Chen, Denis Delić, Yaochen Cao, Zeyu Zhang, Hongwei Wu, Ahmed A Hasan, Mohamed M S Gaballa, Lianghong Yin, Bernhard K Krämer, Thomas Klein, Xin Shi, Ben He, Linghong Shen, Berthold Hocher
It has been suggested that the novel selective phosphodiesterase 9 (PDE9) inhibitor may improve cardiac and renal function by blocking 3',5'-cyclic guanosine monophosphate (cGMP) degradation. 5/6 nephrectomized (5/6Nx) rats were used to investigate the effects of the PDE9 inhibitor (BAY 73-6691) on the heart and kidney. Two doses of BAY 73-6691 (1 mg/kg/day and 5 mg/kg/day) were given for 95 days. The 5/6Nx rats developed albuminuria, a decrease in serum creatinine clearance (Ccr), and elevated serum troponin T levels...
February 2, 2024: Pflügers Archiv: European Journal of Physiology
https://read.qxmd.com/read/38289730/chronic-lithium-toxicity-in-old-age-patients-taking-angiotensin-receptor-blocker-a-case-report
#32
JOURNAL ARTICLE
Asim Pandey, Kunjan Khanal, Anushree Jha, Prava Basnet, Dipesh Bhattarai
UNLABELLED: Chronic lithium toxicity is a potentially serious side effect on patients taking lithium for a prolonged period with the diagnosis of mood disorders. The toxicity is even higher in patients taking drugs that interfere with the metabolism of lithium like angiotensin receptor blockers and in older patients with reduced kidney function. In this report, we present the case of a 62-year-old woman who presented to the emergency department with symptoms including loose stools, generalised body weakness, slurred speech, coarse hand tremors, and dystonia persisting for fifteen days...
November 1, 2023: JNMA; Journal of the Nepal Medical Association
https://read.qxmd.com/read/38285627/three-year-cardiovascular-outcomes-of-telmisartan-in-patients-with-hypertension-an-electronic-health-record-based-cohort-study
#33
JOURNAL ARTICLE
Yunjin Yum, Ju Hyeon Kim, Hyung Joon Joo, Yong Hyun Kim, Eung Ju Kim
BACKGROUND: Telmisartan exhibits superior efficacy in controlling 24-hour blood pressure (BP) compared with other angiotensin receptor blockers (ARBs). However, data on its cardiovascular effects in patients with hypertension are limited. This study aimed to evaluate the cardiovascular outcomes in patients taking telmisartan compared to those taking other ARBs. METHODS: This multicenter retrospective study used data from the Korea University Medical Center database, built from electronic health records...
January 29, 2024: American Journal of Hypertension
https://read.qxmd.com/read/38256891/the-discovery-of-novel-agents-against-staphylococcus-aureus-by-targeting-sortase-a-a-combination-of-virtual-screening-and-experimental-validation
#34
JOURNAL ARTICLE
Kang Liu, Jiangbo Tong, Xu Liu, Dan Liang, Fangzhe Ren, Nan Jiang, Zhenyu Hao, Shixin Li, Qiang Wang
Staphylococcus aureus (S. aureus) , commonly known as "superbugs", is a highly pathogenic bacterium that poses a serious threat to human health. There is an urgent need to replace traditional antibiotics with novel drugs to combat S. aureus . Sortase A (SrtA) is a crucial transpeptidase involved in the adhesion process of S. aureus . The reduction in virulence and prevention of S. aureus infections have made it a significant target for antimicrobial drugs. In this study, we combined virtual screening with experimental validation to identify potential drug candidates from a drug library...
December 29, 2023: Pharmaceuticals
https://read.qxmd.com/read/38231079/standard-of-care-plus-telmisartan-on-respiratory-failure-due-to-covid-19-star-covid-trial
#35
JOURNAL ARTICLE
Abraham E Gracia-Ramos, Gissel Y Ángeles-Durán, Iván R Flores-Gómez, Emmanuel Flores-Martínez, Tania I Valdin-Orozco, Jesús R Reyes-Peralta, César Pedraza-Hervert, Flor A Garcia-Arroyo, Antonio Cortés Ortíz, María J Pecero-Hidalgo
BACKGROUND: The potential influence of renin-angiotensin inhibitors on the severity of SARS-CoV-2 infection has been considered in preclinical and observational studies with contradictory results. Therefore, we investigated the effect of telmisartan in reducing lung injury among hospitalized COVID-19 patients. METHODS: The STAR-COVID trial was conducted as a prospective, parallel-group, randomized, open-label study involving hospitalized adult patients with severe COVID-19 (NCT04510662)...
January 17, 2024: Minerva cardiology and angiology
https://read.qxmd.com/read/38228033/effects-of-telmisartan-on-metabolic-syndrome-components-a-comprehensive-review
#36
REVIEW
Mohsen Imenshahidi, Ali Roohbakhsh, Hossein Hosseinzadeh
Telmisartan is an antagonist of the angiotensin II receptor used in the management of hypertension (alone or in combination with other antihypertensive agents. It belongs to the drug class of angiotensin II receptor blockers (ARBs). Among drugs of this class, telmisartan shows particular pharmacologic properties, including a longer half-life than any other angiotensin II receptor blockers that bring higher and persistent antihypertensive activity. In hypertensive patients, telmisartan has superior efficacy than other antihypertensive drugs (losartan, valsartan, ramipril, atenolol, and perindopril) in controlling blood pressure, especially towards the end of the dosing interval...
February 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38222605/salicylic-acid-conjugate-of-telmisartan-inhibits-chikungunya-virus-infection-and-inflammation
#37
JOURNAL ARTICLE
Rudra Narayan Dash, Amrita Ray, Prabhudutta Mamidi, Saikat De, Tapas K Mohapatra, Alok K Moharana, Tathagata Mukherjee, Soumyajit Ghosh, Subhasis Chattopadhyay, Bharat B Subudhi, Soma Chattopadhyay
There is no approved antiviral for the management of the Chikungunya virus (CHIKV). To develop an antiviral drug that can manage both CHIKV and arthritis induced by it, an ester conjugate of telmisartan (TM) and salicylic acid (SA) was synthesized (DDABT1). It showed higher potency (IC50 of 14.53 μM) and a good selectivity index [(SI = CC50 /IC50 ) > 33]. On post-treatment of DDABT1, CHIKV infection was inhibited significantly by reducing CPE, viral titer, viral RNA, and viral proteins. Further, the time of addition experiment revealed >95% inhibition up to 4hpi indicating its interference predominantly in the early stages of infection...
January 9, 2024: ACS Omega
https://read.qxmd.com/read/38200077/clinical-and-preclinical-evidence-that-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-prevent-diabetic-peripheral-neuropathy
#38
JOURNAL ARTICLE
Shiori Iwane, Wataru Nemoto, Tomoyoshi Miyamoto, Tomonori Hayashi, Masayuki Tanaka, Kazuki Uchitani, Tatsuya Muranaka, Masanori Fujitani, Yuichi Koizumi, Atsushi Hirata, Maho Tsubota, Fumiko Sekiguchi, Koichi Tan-No, Atsufumi Kawabata
Given possible involvement of the central and peripheral angiotensin system in pain processing, we conducted clinical and preclinical studies to test whether pharmacological inhibition of the angiotensin system would prevent diabetic peripheral neuropathy (DPN) accompanying type 2 diabetes mellitus (T2DM). In the preclinical study, the nociceptive sensitivity was determined in leptin-deficient ob/ob mice, a T2DM model. A clinical retrospective cohort study was conducted, using the medical records of T2DM patients receiving antihypertensives at three hospitals for nearly a decade...
January 10, 2024: Scientific Reports
https://read.qxmd.com/read/38197151/clinical-trial-design-for-assessing-hypertension-medications-are-critical-circadian-chronopharmacological-principles-being-taking-into-account
#39
JOURNAL ARTICLE
Ramón C Hermida, Michael H Smolensky, Artemio Mojón, José R Fernández
INTRODUCTION: Clinical hypertension trials typically rely on homeostatic principles, including single time-of-day office blood pressure (BP) measurements (OBPM), rather than circadian chronopharmacological principles, including ambulatory monitoring (ABPM) done around-the-clock to derive the asleep systolic BP (SBP) mean and sleep-time relative SBP decline - jointly the strongest prognosticators of cardiovascular disease (CVD) risk and true definition of hypertension - to qualify participants and assess outcomes...
January 10, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38189344/identification-of-approved-drugs-with-aldh1a1-inhibitory-potential-aimed-at-enhancing-chemotherapy-sensitivity-in-cancer-cells-an-in-silico-drug-repurposing-approach
#40
JOURNAL ARTICLE
Sanjay Kumar Paul, Abdelmadjid Guendouzi, Agniswar Banerjee, Abdelkrim Guendouzi, Rajen Haldar
The aldehyde dehydrogenase 1A1 (ALDH1A1) also known as retinal dehydrogenase, is an enzyme normally involved in the cellular metabolism, development and detoxification processes in healthy cells. However, it's also considered a cancer stem cell marker and its high levels of expression in several cancers, including breast, lung, ovarian, and colon cancer have been associated with poor prognosis and resistance to chemotherapy. Given its crucial role in chemotherapy resistance by detoxification of chemotherapeutic drugs, ALDH1A1 has attracted significant research interest as a potential therapeutic target for cancer...
January 8, 2024: Journal of Biomolecular Structure & Dynamics
keyword
keyword
38258
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.